LENZ Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 5, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 5, 2025

LENZ$4.10-4.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except for shares and par value)

	September 30, 2025	December 31, 2024
(unaudited)
Assets
Current assets:
Cash and cash equivalents	$25,399	$20,158
Marketable securities	176,773	188,872
Inventory	949	—
Prepaid expenses and other current assets	3,876	2,773
Restricted cash	—	114
Total current assets	206,997	211,917
Property and equipment, net	1,258	651
Operating lease right-of-use asset	847	1,338
Other assets	1,602	1,398
Total assets	$210,704	$215,304
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$4,323	$4,257
Accrued liabilities	11,993	6,149
Total current liabilities	16,316	10,406
Operating lease liability, net	461	814
Total liabilities	16,777	11,220
Commitments and contingencies (Note 6)
Stockholders' equity:
Common stock, par value of $0.00001 per share; 300,000,000 shares authorized; 28,588,261 and 27,531,490 shares issued at September 30, 2025 and December 31, 2024, respectively; and 28,588,261 and 27,518,439 shares outstanding at September 30, 2025 and December 31, 2024, respectively	1	1
Additional paid-in capital	384,944	348,901
Accumulated deficit	(191,245)	(145,014)
Accumulated other comprehensive income	227	196
Total stockholders’ equity	193,927	204,084
Total liabilities and stockholders’ equity	$210,704	$215,304

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.